41results about How to "No change in biological activity" patented technology

The invention discloses a single chain DNA oligonucleotide aptamer capable of specifically recognizing aflatoxin B1. The invention provides the single chain DNA oligonucleotide aptamer capable of highly and specifically recognize aflatoxin B1, and aflatoxin B1 in food can be rapidly and accurately detected through a labeling method. In the invention, aflatoxin B1 in food and grain can be taken as a target substance, a nucleic acid aptamer sequence specifically bind to aflatoxin B1 can be obtained by using a SELEX technology, the aptamer can be converted to a report nucleic acid aptamer by labeling report molecule, rapid detection of aflatoxin B1 in food can be realized by routine detection means such as colloidal-gold test paper, fluorescence report detection and an ELISA method, massive synthesis is carried out, chemical modification reconstruction is easily carried out, stability is high, and the single chain DNA oligonucleotide aptamer can be widely used on food detection, base research, clinical diagnosis and medicine research.

The invention belongs to the technical field of medicines, and particularly relates to an effervescent suppository for treating mammal vaginitis. A preparation disclosed by the invention consists of the following components in percentage by weight: 0.01-0.04 percent of recombinant lysostaphin, 10-50 percent of lactose, 5-30 percent of microcrystalline cellulose, 1-20 percent of polyoxyl[40]stearate, 1-10 percent of povidone, 5-40 percent of sodium bicarbonate, 5-40 percent of sodium dihydrogen phosphate and 0.1-5 percent of superfine silica powder. The preparation can disintegrate in an effervescent manner in the presence of body fluid after entering the vagina of a mammal, and medicaments are released rapidly by being mixed in foam, so that the contact area between the medicaments and vaginal mucosa is increased, the medicaments can permeate deep into mucosa folds, the acting time of the medicaments on mucosa is prolonged, the local tissue medicament concentration is increased, the treatment effect is enhanced, and various pathogenic bacteria causing vaginitis are killed effectively.

The invention discloses a method for preparing gamma-aminobutyric acid as raw material of health foods. The method comprises the steps of selecting extract which is rich in gamma-aminobutyric acid after green-tea extraction as raw material, using natural capsule material, coating gamma-aminobutyric acid extract to be microcapsule core substances, forming capsule membrane with the diameter of between 200 and 400 microns, using natural colloid as embedding wall material and utilizing an embedding-method preparation technique for sustained-release microcapsules to produce powdered gamma-aminobutyric acid. The method has the advantages that all components used in the method are natural products, safe and reliable; the gamma-aminobutyric acid is sustained in the acting time of efficacy, balanced in release, little in the loss of functional components, insipid, colorless, free from interference in the own characteristics of foods and medicines, easy to dissolve, good in compatibility and capable of dissolving in water-soluble and fat-soluble products; and the method is simple in preparation process, extensive in raw materials and easy to popularize and apply.

The invention relates to a composition of recombinant polypeptides with different lengths based on screening and construction. The invention discloses a stable and non-structure polypeptide molecule without immunogenicity. The polypeptide molecule comprises 3-6 types of amino acids selected from glycine, alanine, serine, threonine, proline and lysine is designed through a complete artificial method. The polypeptide molecule and a bio-active protein are subjected to fusion expression so that the problem that the original biological activate protein has poor solubility, high immunogenicity or a short half life.

The invention relates the separating agent box and application. The agent box comprises erythrocyte precipitating agent, hypaque sodium- ficoll 400# or HISTOPAQUE1077 and cell maintenance liquid. The agent box can separate bone marrow and umbilical cord blood, on the surface of cell there is no any mark, and it doesn't change biological activity of cell. The invention can commercially manufacture, and the application is wide.

The invention relates to the technical field of food processing, and comprises the following steps: cleaning, drying and pulverizing the slaw liquid milk, extracting flavonoids and alkaloids in the slaw by ultrasonic extraction, and then The vetch extract is mixed with milk, and finally the mixed vetch extract and fresh milk are homogenized, sterilized at ultra-high temperature, cooled, and filled and sealed by a packaging machine. The liquid milk of pigskin is composed of pigskin extract and fresh milk at a volume ratio of 1:30, and the pigskin extract is composed of purified flavonoids, purified alkaloids and water, adding 1 gram of pigskin per liter of water. It is made by mixing the purified flavonoids and 1.5 grams of purified alkaloids. The invention organically combines the flavonoids and alkaloids in the slaw with milk, and scientifically matches them, so that the obtained slaw liquid milk has good taste and has both nutritional value and health care function.

A Method for preparation of sugar biological chip is disclosed that the epoxyethane radical derived solid carrier is covalence coupled with the amidol of coupling agents by the epoxyethane radical contained on the surface, the aldolisation condensation reaction occurred between the hydroxyl which is in the other side of the coupling agents and the deacidizing end of the deacidizing sugar to form the glycosidic bond, the deacidizing sugar is coupled by covalent formula to the solid carrier to form the sugar chip. Or the amidol radical derived solid carrier is covalence coupled with the acid group which is activated by the N-hydroxy succinimide and the dicyclo hexylcar bodiimide of the coupling agents by the amidol radical contained on the surface, the aldolisation condensation reaction occurred between the hydroxy which is in the other side of the coupling agents and the deacidizing end of the deacidizing sugar to form the glycosidic bond, the deacidizing sugar is coupled by covalent formula to the solid carrier to form the sugar chip. The invention resolves the technical matters of that the deacidizing sugar is friable, the Method for preparation is complex, and the cost is high. The invention is simple and quick; the bioactivity of the sugar chip is stable, and easy to apply dimensionally.

The invention belongs to the technical field of medicines, and specifically relates to a suppository for treating mammal endometritis. The preparation disclosed in the invention comprises the following components of: by weight, 0.004-0.01% of staphylococcus lysozyme, 0.1-4% of lysozyme, 10-80% of semisynthetic fatty glyceride, 1-20% of poloxamer 188(F68), 1-20% of HPMC, 5-50% of sodium bicarbonate and 5-50% of sodium dihydrogen phosphate. After the preparation provided by the invention enters into mammal uterus through administration, the preparation can undergo effervescence decomposition in a body fluid. The medicine is mixed in foams and rapidly released. Contact area between the medicine and mucosal of uterus becomes larger and the medicine can penetrate into deep portions of mucosa wrinkles so as to prolong the action time between the medicine and the mucosa, raise the concentration of the medicine on local tissues, further enhance the curative effect and effectively kill various pathogens which can cause endometritis.

The invention discloses a biological antibacterial polypeptide preparation as well as a preparation method and application of the biological antibacterial polypeptide preparation. The biological antibacterial polypeptide preparation takes water as a carrier and is prepared from the following components in percentage by weight: 0.1 percent to 10 percent of a biological antibacterial peptide BQ and 0.01 percent to 1 percent of polyhexamethylene biguanidine. The biological antibacterial polypeptide preparation has good sterilization effect. A core sterilization component of the preparation is a novel antibacterial peptide and has very high sterilization effect on staphylococcus aureus, escherichia coli, candida albicans and viruses. When an in-vitro experiment is carried out for 2min to 5min, 99.9 percent of sterilization rate can be realized. The biological antibacterial polypeptide preparation has high safety, has no toxicity to or residues to human bodies, has high stability and can be used as a prevention medicine. The main acting component is a biological preparation and the disadvantages that a traditional chemical preparation has irritation on mucosa and bacteria easily have drug resistance are overcome. The biological antibacterial polypeptide preparation is easily accepted by organisms, has no toxic side effect and is suitable for long-time utilization or used as the prevention medicine.

The invention discloses a single-stranded DNA oligonucleotide aptamer that specifically recognizes aflatoxin B1; the purpose of the invention is to provide a single-stranded DNA oligonucleotide that can highly specifically recognize aflatoxin B1 The acid aptamer can quickly and accurately detect aflatoxin B1 in food through the labeling method. In the present invention, the common aflatoxin B1 in foods and grains is used as a target substance, and a nucleic acid aptamer sequence specifically binding to aflatoxin B1 is obtained by using SELEX technology, and the aptamer can be transformed by labeling a reporter molecule In order to report nucleic acid aptamers, combined with conventional detection methods such as gold standard test paper, fluorescent reporter detection, and enzyme-linked immunoassay technology (ELISA method), the rapid detection of aflatoxin B1 in food can be realized, and it can be synthesized in large quantities and is easy It is chemically modified and has high stability, and is widely used in food testing, basic research, clinical diagnosis, and drug research.

A preparation method of a weikang capsule comprises processing steps as follows: (1), 64 g of rhizoma bletillae, 63 g of cuttlebone, 38 g of endothelium corneum gigeriae galli, 1 g of stir-fried egg shells and 13 g of plant soot are taken and subjected to ultrafine grinding for standby; (2), 63 g of frankincense and 15 g of myrrh are taken and ground by an ultralow-temperature grinder for standby; (3) 64 g of pseudo-ginseng and 64 g of rhizoma cyperi are taken and ground into fine powder, ethyl alcohol which accounts for 3-4 times of the quantity of the and has the mass concentration of 65%-85% are added into the fine powder, the fine powder is soaked for 3-4 hours and subjected to ultrasonic continuous countercurrent extraction for 30-60 min, and an extraction liquid is filtered for standby; (4), 63 g of radix astragali and 64 g of radix paeoniae alba are taken and put into an extraction tank, water accounting for 8 times of the quantity of the mixture is added for decoction extraction for two hours, and the extraction liquid is filtered for standby; and (5), the step (3) and the step (4) are combined, thick paste is obtained, the ultrafine powder of the step (1) and the step (2) is added and uniformly mixed, and particles are prepared. According to the method, bioavailability of a human body can be improved, and the production cycle can be shortened while effective ingredients are extracted to the greatest extent.

The invention relates to a preparation method of astaxanthin-rich haematococcus pluvialis oil, and belongs to the technical field of compound extraction. The method comprises the following steps of (1) pretreating raw materials; (2) preparing an enzymolysis system; (3) performing enzymolysis treatment; and (4) performing enrichment process. According to the method, the enrichment of astaxanthin in haematococcus pluvialis oil is efficiently realized by adopting a method of combining enzymolysis with heterogeneous purification, and the content of total astaxanthin substances in a finally prepared product is more than 40%, so that the dosage requirement in the application process of the product is well met.

The invention discloses a thymalfasin (T[alpha]1) polyethylene glycol polymer, a medicine composition including same, and an application thereof. The T[alpha]1 polyethylene glycol polymer is represented as the following general formula. In the invention, the T[alpha]1 is synthesized through a regular solid phase synthesis method, wherein the last one step, acetylation, is replaced by introducing a maleimide active group, which can be specifically coupled with monosulfydryl polyethylene glycol at room temperature to prepare a polymer. The T[alpha]1 polyethylene glycol polymer not changes the biostructure of T[alpha]1 and also not changes the bioactivity of the T[alpha]1, and significantly increases the half-life period of the polymer. The method has simple process, is easy to industrialize, has gentle reaction conditions, is more than 95% in molar yield and has excellent market prospect.